Cellular Biomedicine Group (CBMG) Misses Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Cellular Biomedicine Group Reports Second Quarter and First Half 2015 Financial Results and Business Highlights
August 14, 2015 7:00 AM EDTSHANGHAI, China and PALO ALTO, Calif., Aug. 14, 2015 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biomedicine firm engaged in the development of effective stem cell therapies for degenerative diseases and immunotherapies for cancer, today reported financial results and business highlights for the quarter and six months ended June 30, 2015.
"I am pleased with our second quarter progress in reaching certain planned milestones and in strengthening both our business and technological advantages," said Dr. William (Wei) Cao, Chief Executive Officer of Cellular Biomedicine Group. "In addition to our international-standard... More
Cellular Biomedicine Group Reports Second Quarter and First Half 2015 Financial Results and Business Highlights
August 14, 2015 7:00 AM EDTSHANGHAI, China and PALO ALTO, Calif., Aug. 14, 2015 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biomedicine firm engaged in the development of effective stem cell therapies for degenerative diseases and immunotherapies for cancer, today reported financial results and business highlights for the quarter and six months ended June 30, 2015.
"I am pleased with our second quarter progress in reaching certain planned milestones and in strengthening both our business and technological advantages," said Dr. William (Wei) Cao, Chief Executive Officer of Cellular Biomedicine Group. "In addition to our international-standard... More
